Literature DB >> 32890137

Considerations for Child Cancer Survivors and Immunocompromised Children to Prevent Secondary HPV-associated Cancers.

Teresa M Imburgia1,2, Marcia L Shew1, Patti E Gravitt3, Rachel A Katzenellenbogen1.   

Abstract

Survivors of childhood cancer and other immunocompromised children are at high risk for the development of secondary human papillomavirus (HPV)-associated cancers. In this overview, the authors examine the epidemiology of vaccine efficacy, the natural history of HPV infections, and accelerated HPV-associated cancer development in these populations. The authors highlight the opportunities for preventive care and future research directives.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 32890137     DOI: 10.1097/TP.0000000000003444

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial.

Authors:  Wendy Landier; Smita Bhatia; F Lennie Wong; Jocelyn M York; Jessica S Flynn; Harrison M Henneberg; Purnima Singh; Kandice Adams; Karen Wasilewski-Masker; Brooke Cherven; Rama Jasty-Rao; Marcia Leonard; James A Connelly; Saro H Armenian; Leslie L Robison; Anna R Giuliano; Melissa M Hudson; James L Klosky
Journal:  Lancet Child Adolesc Health       Date:  2021-11-10

2.  Human papillomavirus (HPV) vaccination is cancer prevention for childhood cancer survivors.

Authors:  Heather M Brandt; Deanna Kepka; Anne C Kirchhoff; Casey L Daniel; Neel S Bhatt
Journal:  Cancer       Date:  2021-10-04       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.